Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

Phase 1

Active, not recruiting

• Conditions: Hormone Receptor Positive Metastatic Breast Cancer

• Registration Number: NCT03988595
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that exercise helps delay the development of resistance to hormone therapy while slowing the growth of tumors.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-06-12
• Study First Submitted: 2019-06-13
• Study First Submitted QC: 2019-06-13
• Study First Posted: 2019-06-17
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-01
• Last Update Posted: 2025-07-02
• Primary Completion: 2025-08-01
• Study Completion: 2025-08-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Female
• Target Recruitment: 54

Inclusion Criteria

• Patients with histologically-confirmed, HR-positive (ER and/or PR), HER2-negative metastatic breast cancer (MBC)
• Postmenopausal status defined by lack of menses for 2 years, oophorectomy, or medical ovarian suppression
• Receiving first line endocrine-based therapy (tamoxifen, aromatase inhibitor, or fulvestrant; concurrent molecular therapy also allowed)
• Sedentary (i.e., <60 minutes / week of exercise)
• Age >18 years
• BMI ≥ 18.5
• Cleared for exercise participation as per screening clearance via PAR-Q+
• Cleared for study participation as per screening consultation with an MSK Exercise Physiologist
• Willingness to comply with all study-related procedures
• Patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled

Exclusion Criteria

• Life expectancy <6 months
• Enrollment onto any other therapeutic investigational study
• Mental impairment leading to inability to cooperate
• Concurrent participation in weight loss or other exercise programs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
maximum feasible dose (MFD)	24 weeks	Feasibility is defined in terms of the relative dose intensive (RDI), the proportion of the planned exercise prescription that was completed without requiring a dose modification or interruption. The MFD is defined as the dose estimated to result in approximately 70% of patients achieving an RDI ≥ 75%.

Trial Locations

Locations (10)

Indiana University (Data Collection Only); 🇺🇸 Indianapolis, Indiana, United States

Johns Hopkins Hospital (Data Collection Only); 🇺🇸 Baltimore, Maryland, United States

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities); 🇺🇸 Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities); 🇺🇸 Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities); 🇺🇸 Montvale, New Jersey, United States

Montefiore Health Systems (Montefiore Medical Center) (Data Collection Only); 🇺🇸 Bronx, New York, United States

Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity); 🇺🇸 Commack, New York, United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities); 🇺🇸 Harrison, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities); 🇺🇸 Uniondale, New York, United States